Health care professionals can have a powerful impact on labeling requirements for drugs by formally petitioning the FDA for ...

The U.S. Food and Drug Administration has approved an updated label for Unloxcyt (cosibelimab-ipdl) for the treatment of ...

The drugs have soared in popularity, with some men taking them for unapproved uses like anti-aging or increasing muscle mass.

Shares in Sarepta reversed some of their recent declines after the FDA added a warning label to its Duchenne muscular dystrophy (DMD) gene therapy, ending a protracted period of uncertainty for the ...

More recently, the FDA posted two two letters: one backdated for September 9, regarding GSK’s HIV medication Apretude and one ...

US drugmaker Pfizer has brought its Rimegepant (Orally Disintegrating Tablet -ODT) to India, to treat acute migraine, in adults with a previous insufficient response to triptan. “The new medication ...

Pfizer launches new migraine drug in India (Image Source: Freepik) Drug maker Pfizer on Monday introduced a new migraine treatment in India, offering hope to millions who struggle with severe and ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The FDA has restricted the ...

https://www.thehindubusinessline.com/companies/pfizer-launches-new-medication-for-migraine-treatment/article70290052.ece Copy Drug maker Pfizer on Monday said it has ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The FDA has restricted the type ...

Based on this analysis, all 3 gepants are not cost-effective compared with usual care for the treatment of acute migraine. Objective: Migraine is a debilitating chronic disorder requiring multifaceted ...

Migraine is a growing public health concern in India. According to a study published in The Journal of Headache and Pain, nearly 26.3% of people in Delhi NCR suffer from the condition. Pfizer on ...